Bortezomib-Responsive Refractory Anti-N-Methyl-d-Aspartate Receptor Encephalitis.
Pediatr Neurol
; 103: 61-64, 2020 02.
Article
em En
| MEDLINE
| ID: mdl-31759783
ABSTRACT
BACKGROUND:
Anti-N-methyl-d-aspartate receptor encephalitis is a central nervous system inflammatory autoimmune disease affecting adults and children. The use of first- and second-line immunotherapies is supported. Recent reports suggest the efficacy of bortezomib in severe anti-N-methyl-d-aspartate encephalitis in adult patients not responsive to second-line treatment; there are no data about pediatric patients. PATIENT DESCRIPTION We describe an eight-year-old child with anti-N-methyl-d-aspartate encephalitis not responsive to first- and second-line treatments who experienced marked clinical improvement after bortezomib administration.DISCUSSION:
Bortezomib is a selective and reversible inhibitor of the 26S proteasome, which is used to treat oncologic and rare autoimmune disorders in pediatric patients. As observed in adult patients, bortezomib administration induced anti-N-methyl-d-aspartate antibody titer decline and clinical improvement with an acceptable risk profile.CONCLUSION:
This is the first report of the use of bortezomib in children with anti-N-methyl-d-aspartate encephalitis; it could be a useful therapeutic option in children with refractory anti-N-methyl-d-aspartate encephalitis.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Encefalite Antirreceptor de N-Metil-D-Aspartato
/
Bortezomib
/
Imunossupressores
Limite:
Child
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article